Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-predictable routine of deadlines, meetings, Skype calls, and whatever else you do to communicate has, of course, returned. To cope, yes, we are firing up the coffee kettle and quaffing cups of stimulation. After all, the neurons can use a little help. Our choice today is blueberry cobbler for those considering something adventurous. Meanwhile, here are some items of interest to help you on your own journey. Hope all goes well and, by all means, keep in touch. We enjoy hearings spilled secrets …

The appointment of a former pharmaceutical lobbyist to the National Institute on Drug Abuse’s top advisory body has outraged recovery advocates, who blame the industry for a nationwide overdose crisis that claimed more than 67,000 lives last year, BuzzFeed News writes. Jessica Hulsey Nickel, 43, heads the Brimley Group lobbying firm and the nonprofit Addiction Policy Forum. From 2014 to 2017, she was a registered lobbyist for Alkermes (ALKS), which makes the Vivitrol addiction treatment that sparked controversy over misleading marketing aimed at judges and jails.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy